Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSC) Equity Ratio (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Equity Ratio for 6 consecutive years, with 0.28 as the latest value for Q3 2025.

  • On a quarterly basis, Equity Ratio fell 60.76% to 0.28 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.28, a 60.76% decrease, with the full-year FY2024 number at 0.66, up 375.5% from a year prior.
  • Equity Ratio was 0.28 for Q3 2025 at Ensysce Biosciences, down from 0.55 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.7 in Q3 2024 to a low of 0.77 in Q3 2022.
  • A 5-year average of 0.14 and a median of 0.28 in 2025 define the central range for Equity Ratio.
  • Peak YoY movement for Equity Ratio: plummeted 1853.89% in 2022, then surged 1831.42% in 2024.
  • Ensysce Biosciences' Equity Ratio stood at 0.5 in 2021, then crashed by 37.8% to 0.68 in 2022, then surged by 64.88% to 0.24 in 2023, then skyrocketed by 375.5% to 0.66 in 2024, then tumbled by 58.48% to 0.28 in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Equity Ratio are 0.28 (Q3 2025), 0.55 (Q2 2025), and 0.59 (Q1 2025).